First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer
Csiki, Ildiko, Dong, Aiwen, Tuan, Bertrand Y., John, Elizabeth, O'Toole, Leslie, Seppa, Judy, Huang, Ningwu, Hawley, Ronald C., Exon, Chris, Glenn, Jeffrey S., Klumpp, Klaus
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article